Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status.

por Gillian Farnie, Pamela M Willan, Robert B Clarke, Nigel J Bundred
Publicado 2013

FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity

por Simon Timbrell, Hosam Aglan, Angela Cramer, Phil Foden, David Weaver, Jonathan Pachter, Aoife Kilgallon, Robert B. Clarke, Gillian Farnie, Nigel J. Bundred
Publicado 2021